The video above also alluded to only needing FDA approval for...

The video above also alluded to only needing FDA approval for each of the modified main cell types, eg T Cell, NK cell.

I raised this Q's last year (unsure if before or after this presentation) regarding both the number of antigens they have tried (if more than 3 then get diminished retuns as not enough of each to effectively work) and if would require separate trial for each potential combination.

SYC said that even if they did require separate trials, which classed as a worst case senario it would still be manageable.

I guess we will find out more during the IND submission for AML which is already using 2 indications, albeit they do look to be unique to AML.

Perhaps the Her2 study might be run as a basket approach to target all Her2+ including breast, bladder, pancreatic, ovarian and stomach. This is where Cell Pryme-A and Cell-Pryme M will come into their own to assist with the tumour macro environment and cell longevity.